2015 American Transplant Congress
Refinement of Non-Invasive Diagnostic Criteria to Differentiate Tumor from Bland Portal Vein Thrombosis Before Liver Transplant in Patients With Hepatocellular Carcinoma
University of California San Francisco, San Francisco, CA.
Differentiating tumor vs bland portal vein thrombosis (PVT) is essential in determining liver transplant (LT) candidacy for patients with hepatocellular carcinoma (HCC). The primary aim…2015 American Transplant Congress
SBRT(Stereotactic Body Radiotherapy) to Bridge or Down-Size HCC for Liver Transplantation
Twenty seven (27) pts with HCC and cirrhosis have been treated with SBRT with intent for liver transplantation since 2010 at Allegheny Health Network. Nineteen…2015 American Transplant Congress
The Extended Toronto Criteria for Transplantation for Hepatocellular Carcinoma. A Validation Study
Multi-Organ Transplant, Toronto General Hospital. University of Toronto, Toronto, ON, Canada.
Liver transplant (LT) listing criteria for patients with hepatocellular cancers (HCC) that exceed the Milan criteria are still controversial. At the University of Toronto, we…2015 American Transplant Congress
Associations Between Sirolimus Use and Outcomes After Liver Transplant for Hepatocellular Carcinoma
A growing fraction of U.S. liver transplants are being done for the indication of hepatocellular carcinoma (HCC). HCC recurrence after transplant remains a major concern…2015 American Transplant Congress
Pretransplant Elevated Plasma Fibrinogen Level Is Associated With Tumor Recurrence and Poor Prognosis in Hepatocellular Carcinoma Patients After Liver Transplantation
Background and Objective: Elevated plasma fibrinogen (FBG) level is associated with tumor progression and poor patient outcomes in several cancers. The aim of this study…2015 American Transplant Congress
Impact of Everolimus On the Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation When Used in Early Stage: A Single Center Prospective Study
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan.
Background:Liver transplantation is only treatment for unresectable hepatocellular carcinoma (HCC). However, postoperative immunosuppression may act as an additional risk factor for tumour recurrence. Antineoplastic role…2015 American Transplant Congress
Predictors of Time to Recurrence and Mortality Associated With Recurrent Hepatocellular Carcinoma After Liver Transplantation
Transplantation, UCLA, Los Angeles, CA.
Background: While recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) portends a poor prognosis, adjuvant therapy may prolong survival. We sought to identify factors that…2015 American Transplant Congress
Clinical Impact of 18F-FDG-PET/CT in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma
Liver Cancer Center, National Cancer Center, Goyang, Korea.
Background: The relevant number of patients with hepatocellular carcinoma (HCC) beyond the Milan criteria has undergone living donor liver transplantation (LDLT). However, the prognostic factors…2015 American Transplant Congress
Adoptive Immunotherapy With Liver Allograft-Derived NK Cells Improves Recurrence-Free Survival After Living-Donor Liver Transplantation in Patients With Hepatocellular Carcinoma
Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Introduction: Previous studies revealed that the recurrence rate of hepatocellular carcinoma (HCC) was still 10–20%, even among liver transplantation (LT) recipients meeting the Milan criteria…2015 American Transplant Congress
Liver Transplantation for Hepatocellular Carcinoma inside Milan Criteria: Lower Recurrence in Patients With Hepatitis C Infection
Mayo Clinic, Jacksonville, FL.
Purpose: Hepatitis C infection (HCV) related-cirrhosis can lead to hepatocellular carcinoma (HCC). Liver transplantation (LT) is the optimal treatment for selected patients with HCC, providing…
American Transplant Congress abstracts